Napredna pretraga

Pregled bibliografske jedinice broj: 688158

Clinical relevance of anemia treatment in patients with chronic kidney disease - an experience from a tertiary care center in Croatia


Vuksanović-Mikuličić, Sretenka; Mikolašević, Ivana; Orlić, Lidija; Bubić, Ivan; Jelić, Ita; Rački, Sanjin
Clinical relevance of anemia treatment in patients with chronic kidney disease - an experience from a tertiary care center in Croatia // Bantao Journal / Spasovski, Goce (ur.).
Timisoara, Romania: Bantao, 2013, 2013. str. 66-66 (poster, međunarodna recenzija, sažetak, stručni)


Naslov
Clinical relevance of anemia treatment in patients with chronic kidney disease - an experience from a tertiary care center in Croatia

Autori
Vuksanović-Mikuličić, Sretenka ; Mikolašević, Ivana ; Orlić, Lidija ; Bubić, Ivan ; Jelić, Ita ; Rački, Sanjin

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Bantao Journal / Spasovski, Goce - Timisoara, Romania : Bantao, 2013, 2013, 66-66

Skup
11. Congress Bantao

Mjesto i datum
Timisoara, Rumunjska, 26.-29.09.2013

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Chronic renal disease; anaemia; erythropoietin

Sažetak
INTRODUCTION: In the last ten years or so, there has been a steady increase in the number of patients with chronic kidney and those with end-stage chronic renal failure who require some form of renal replacement therapy. Anaemia is a well-known consequence of chronic kidney disease: its frequency increases with the progression of renal failure and occurs in up to 95% of patients in the final stages of chronic kidney disease. The greatest advance in the treatment of renal anaemia in recent years has been made by the introduction of erythropoietin preparations, the application of which has significantly improved the patients' quality of life. The aim of this study was to analyse whether the treatment of renal anaemia in chronic kidney disease patients not treated by dialysis affects the outcome of their treatment, reduces the incidence of cardiovascular diseases, delays the need for dialysis, reduces morbidity and mortality, and reduces the incidence of adverse cardiovascular events. SUBJECTS AND METHODS: The subjects were patients with chronic kidney disease who come for regular outpatient control at the Department of Nephrology and Dialysis of the Rijeka Clinical Hospital Centre. The patients were divided in two groups. The first group included patients whose renal anaemia was treated with erythropoietin, and the other patients whose anaemia of chronic kidney disease was treated in any other way, regardless of the reason for the exclusion of erythropoietin. Each group included 31 patients with chronic kidney disease. During two years, each patient's laboratory parameters of treatment of chronic renal disease and renal anaemia were monitored at intervals not longer than six months. As well, each patient's number of hospitalisations was recorded, taking into account the cause of hospitalisation and the number of days spent in hospital. RESULTS: During the two years' period, 62 patients with chronic kidney disease were analysed (31 patients in the group who received erythropoietin and 31 patients in the group who did not receive erythropoietin preparation). The mean age in the group who received erythropoietin preparation was 66 ± 13.5, and 68 ± 13.6.in the group of patients who did not receive erythropoietin. The former group was composed of 70% men and 30% women, and the latter of 53% men and 47% women. Examination of comorbid conditions (diabetes, hypertension, hyperlipoproteinemia and previous stroke) revealed no statistically significant differences between the two groups of patients. Likewise, there were no statistically significant differences in changes in biochemical parameters (Fe, ferritin levels, CRP, albumin, calcium, phosphorus) between the two groups of patients over the two-year period. There was neither any statistically significant difference between the two groups of patients in their glomerular filtration rate after the two years, but a tendency of slower progression of renal failure was observed in patients who received erythropoietin as compared to those who did not receive erythropoietin preparation. Moreover, the number of hospitalisations due to adverse cardiovascular events was statistically significantly lower in patients who received erythropoietin, while there was no statistically significant difference in the total number of hospitalisations, hospitalisations for other indications (infection, bleeding, and worsening renal failure), or the total number of days spent in hospital, regardless of the indication. CONCLUSION: The number of patients with chronic kidney disease and those with end-stage renal failure requiring renal replacement therapy is increasing. Renal anaemia, which occurs as a consequence of chronic kidney disease, is associated with increased morbidity and mortality, and with reduced quality of life of these patients. Consequently, it is necessary to recognise this condition and apply the appropriate treatment early in order to prolong life and improve the quality of life of patients with chronic kidney disease.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Klinički bolnički centar Rijeka

Časopis indeksira:


  • Scopus